{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T10:33:47Z","timestamp":1783420427842,"version":"3.54.6"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100006928","name":"Ohio State University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006928","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.ejmech.2020.113135","type":"journal-article","created":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T23:01:38Z","timestamp":1610060498000},"page":"113135","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Design, synthesis, and evaluation of liver-specific gemcitabine prodrugs for potential treatment of hepatitis C virus infection and hepatocellular carcinoma"],"prefix":"10.1016","volume":"213","author":[{"given":"Anthony A.","family":"Stephenson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Taggart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinod P.","family":"Vyavahare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zucai","family":"Suo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2020.113135_bib1","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.tim.2010.11.005","article-title":"Assembly of infectious hepatitis C virus particles","volume":"19","author":"Bartenschlager","year":"2011","journal-title":"Trends Microbiol."},{"key":"10.1016\/j.ejmech.2020.113135_bib2","series-title":"Global Hepatitis Report 2017","year":"2017"},{"key":"10.1016\/j.ejmech.2020.113135_bib3","doi-asserted-by":"crossref","first-page":"S135","DOI":"10.1002\/hep.1840360718","article-title":"Treatment of chronic hepatitis C: a systematic review","volume":"36","author":"Chander","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.ejmech.2020.113135_bib4","first-page":"5","article-title":"Cancer statistics","volume":"65","author":"Siegel","year":"2015","journal-title":"CA A Cancer J. Clin."},{"key":"10.1016\/j.ejmech.2020.113135_bib5","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1200\/JCO.1997.15.6.2403","article-title":"Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial","volume":"15","author":"Burris","year":"1997","journal-title":"J.\u00a0Clin. Oncol. : Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2020.113135_bib6","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1634\/theoncologist.4-3-241","article-title":"Gemcitabine: single-agent and combination therapy in non-small cell lung cancer","volume":"4","author":"Sandler","year":"1999","journal-title":"Oncol."},{"key":"10.1016\/j.ejmech.2020.113135_bib7","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1053\/j.seminoncol.2005.06.025","article-title":"Gemcitabine plus paclitaxel in breast cancer","volume":"32","author":"Yardley","year":"2005","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.ejmech.2020.113135_bib8","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/j.1464-410X.2011.10880.x","article-title":"Intravesical gemcitabine therapy for non-muscle invasive bladder cancer (NMIBC): a systematic review","volume":"109","author":"Shelley","year":"2012","journal-title":"BJU Int."},{"key":"10.1016\/j.ejmech.2020.113135_bib9","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1053\/j.seminoncol.2005.06.023","article-title":"Gemcitabine and carboplatin in second-line ovarian cancer","volume":"32","author":"Ozols","year":"2005","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.ejmech.2020.113135_bib10","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s10555-007-9044-4","article-title":"The role of nucleoside transporters in cancer chemotherapy with nucleoside drugs","volume":"26","author":"Zhang","year":"2007","journal-title":"Canc. Metastasis Rev."},{"key":"10.1016\/j.ejmech.2020.113135_bib11","first-page":"1201","article-title":"Human equilibrative nucleoside transporter 1 is associated with the chemosensitivity of gemcitabine in human pancreatic adenocarcinoma and biliary tract carcinoma cells","volume":"17","author":"Mori","year":"2007","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.ejmech.2020.113135_bib12","first-page":"5000","article-title":"Nucleoside transporter profiles in human pancreatic cancer cells: role of hCNT1 in 2\u2019,2\u2019-difluorodeoxycytidine- induced cytotoxicity","volume":"9","author":"Garcia-Manteiga","year":"2003","journal-title":"Clin. Canc. Res. : Off. J. Am. Assoc. Canc. Res."},{"key":"10.1016\/j.ejmech.2020.113135_bib13","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1016\/j.bcp.2004.07.042","article-title":"Polymerization of the triphosphates of AraC, 2\u2019,2\u2019-difluorodeoxycytidine (dFdC) and OSI-7836 (T-araC) by human DNA polymerase alpha and DNA primase","volume":"68","author":"Richardson","year":"2004","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2020.113135_bib14","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/0006-2952(93)90566-F","article-title":"2\u2019,2\u2019-Difluoro-deoxycytidine (gemcitabine) incorporation into RNA and DNA of tumour cell lines","volume":"46","author":"Ruiz van Haperen","year":"1993","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2020.113135_bib15","first-page":"6110","article-title":"Action of 2\u2019,2\u2019-difluorodeoxycytidine on DNA synthesis","volume":"51","author":"Huang","year":"1991","journal-title":"Canc. Res."},{"key":"10.1016\/j.ejmech.2020.113135_bib16","doi-asserted-by":"crossref","first-page":"15339","DOI":"10.1074\/jbc.M800310200","article-title":"Kinetic investigation of the inhibitory effect of gemcitabine on DNA polymerization catalyzed by human mitochondrial DNA polymerase","volume":"283","author":"Fowler","year":"2008","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2020.113135_bib17","doi-asserted-by":"crossref","first-page":"409","DOI":"10.2174\/156800906777723949","article-title":"Ribonucleotide reductase inhibitors and future drug design","volume":"6","author":"Shao","year":"2006","journal-title":"Curr. Cancer Drug Targets"},{"key":"10.1016\/j.ejmech.2020.113135_bib18","first-page":"3","article-title":"Gemcitabine: preclinical pharmacology and mechanisms of action","volume":"23","author":"Plunkett","year":"1996","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.ejmech.2020.113135_bib19","doi-asserted-by":"crossref","first-page":"3761","DOI":"10.1158\/0008-5472.CAN-03-3363","article-title":"An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines","volume":"64","author":"Davidson","year":"2004","journal-title":"Canc. Res."},{"key":"10.1016\/j.ejmech.2020.113135_bib20","first-page":"11","article-title":"Gemcitabine: a modulator of intracellular nucleotide and deoxynucleotide metabolism","volume":"22","author":"Heinemann","year":"1995","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.ejmech.2020.113135_bib21","first-page":"1340","article-title":"Forced expression of cytidine deaminase confers resistance to cytosine arabinoside and gemcitabine","volume":"24","author":"Neff","year":"1996","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.ejmech.2020.113135_bib22","first-page":"3","article-title":"Gemcitabine: metabolism, mechanisms of action, and self-potentiation","volume":"22","author":"Plunkett","year":"1995","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.ejmech.2020.113135_bib23","first-page":"533","article-title":"Cellular elimination of 2\u2019,2\u2019-difluorodeoxycytidine 5\u2019-triphosphate: a mechanism of self-potentiation","volume":"52","author":"Heinemann","year":"1992","journal-title":"Canc. Res."},{"key":"10.1016\/j.ejmech.2020.113135_bib24","first-page":"371","article-title":"Pretreatment deoxycytidine kinase levels predict in\u00a0vivo gemcitabine sensitivity","volume":"1","author":"Kroep","year":"2002","journal-title":"Mol. Canc. Therapeut."},{"key":"10.1016\/j.ejmech.2020.113135_bib25","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.bbrc.2012.03.122","article-title":"DCK is frequently inactivated in acquired gemcitabine-resistant human cancer cells","volume":"421","author":"Saiki","year":"2012","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejmech.2020.113135_bib26","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1021\/mp300370t","article-title":"Gemcitabine versus Modified Gemcitabine: a review of several promising chemical modifications","volume":"10","author":"Moysan","year":"2012","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejmech.2020.113135_bib27","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1111\/bcp.13849","article-title":"Determinants of the interindividual variability in serum cytidine deaminase activity of patients with solid tumours","volume":"85","author":"Cohen","year":"2019","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejmech.2020.113135_bib28","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1007\/s00280-015-2819-3","article-title":"Influence of infusion method on gemcitabine pharmacokinetics: a controlled randomized multicenter trial","volume":"76","author":"Simon","year":"2015","journal-title":"Canc. Chemother. Pharmacol."},{"key":"10.1016\/j.ejmech.2020.113135_bib29","doi-asserted-by":"crossref","first-page":"3529","DOI":"10.1158\/1078-0432.CCR-07-4885","article-title":"Modulation of gemcitabine (2\u2019,2\u2019-difluoro-2\u2019-deoxycytidine) pharmacokinetics, metabolism, and bioavailability in mice by 3,4,5,6-tetrahydrouridine","volume":"14","author":"Beumer","year":"2008","journal-title":"Clin. Canc. Res. : Off. J. Am. Assoc. Canc. Res."},{"key":"10.1016\/j.ejmech.2020.113135_bib30","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/978-1-4615-5381-6_127","article-title":"Role of deoxycytidine kinase (dCK), thymidine kinase 2 (TK2), and deoxycytidine deaminase (dCDA) in the antitumor activity of gemcitabine (dFdC)","volume":"431","author":"Kroep","year":"1998","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.ejmech.2020.113135_bib31","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/j.1365-2125.2010.03838.x","article-title":"Equilibrative nucleoside transporter 1 genotype, cytidine deaminase activity and age predict gemcitabine plasma clearance in patients with solid tumours","volume":"71","author":"Gusella","year":"2011","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejmech.2020.113135_bib32","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/phar.1194","article-title":"The role of human carboxylesterases in drug metabolism: have we overlooked their importance?","volume":"33","author":"Laizure","year":"2013","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ejmech.2020.113135_bib33","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1021\/acscentsci.7b00069","article-title":"The ecstasy and agony of assay interference compounds","volume":"3","author":"Aldrich","year":"2017","journal-title":"ACS Cent. Sci."},{"key":"10.1016\/j.ejmech.2020.113135_bib34","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1124\/pr.58.3.10","article-title":"Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies","volume":"58","author":"Chou","year":"2006","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.ejmech.2020.113135_bib35","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1146\/annurev.pharmtox.38.1.257","article-title":"The mammalian carboxylesterases: from molecules to functions","volume":"38","author":"Satoh","year":"1998","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.ejmech.2020.113135_bib36","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1016\/S0968-0896(00)00087-0","article-title":"The design and synthesis of a new tumor-selective fluoropyrimidine carbamate, capecitabine","volume":"8","author":"Shimma","year":"2000","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.113135_bib37","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0166-0934(03)00134-4","article-title":"A\u00a0replicon-based bioassay for the measurement of interferons in patients with chronic hepatitis C","volume":"110","author":"Vrolijk","year":"2003","journal-title":"J.\u00a0Virol Methods"},{"key":"10.1016\/j.ejmech.2020.113135_bib38","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1158\/1535-7163.MCT-06-0160","article-title":"Intracellular inhibition of carboxylesterases by benzil: modulation of CPT-11 cytotoxicity","volume":"5","author":"Hyatt","year":"2006","journal-title":"Mol. Canc. Therapeut."},{"key":"10.1016\/j.ejmech.2020.113135_bib39","doi-asserted-by":"crossref","first-page":"2906","DOI":"10.1021\/jm049011j","article-title":"Identification and characterization of novel benzil (diphenylethane-1,2-dione) analogues as inhibitors of mammalian carboxylesterases","volume":"48","author":"Wadkins","year":"2005","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.113135_bib40","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/0006-2952(69)90050-1","article-title":"Inhibition of phenacetin- and acetanilide-induced methemoglobinemia in the rat by the carboxylesterase inhibitor bis-[p-nitrophenyl] phosphate","volume":"18","author":"Buch","year":"1969","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2020.113135_bib41","doi-asserted-by":"crossref","first-page":"369","DOI":"10.3109\/00498251003706598","article-title":"Utility of the carboxylesterase inhibitor bis-para-nitrophenylphosphate (BNPP) in the plasma unbound fraction determination for a hydrolytically unstable amide derivative and agonist of the TGR5 receptor","volume":"40","author":"Eng","year":"2010","journal-title":"Xenobiotica"},{"key":"10.1016\/j.ejmech.2020.113135_bib42","doi-asserted-by":"crossref","first-page":"14769","DOI":"10.1074\/jbc.272.23.14769","article-title":"Purification and cloning of a broad substrate specificity human liver carboxylesterase that catalyzes the hydrolysis of cocaine and heroin","volume":"272","author":"Pindel","year":"1997","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2020.113135_bib43","doi-asserted-by":"crossref","DOI":"10.3390\/molecules23102608","article-title":"Synthesis of gemcitabine-threonine amide prodrug effective on pancreatic cancer cells with improved pharmacokinetic properties","volume":"23","author":"Hong","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2020.113135_bib44","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.2147\/DDDT.S40310","article-title":"Daclatasvir: potential role in hepatitis C","volume":"7","author":"Lee","year":"2013","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.ejmech.2020.113135_bib45","doi-asserted-by":"crossref","first-page":"11149","DOI":"10.1074\/jbc.M111392200","article-title":"Hepatitis C virus (HCV) NS5A binds RNA-dependent RNA polymerase (RdRP) NS5B and modulates RNA-dependent RNA polymerase activity","volume":"277","author":"Shirota","year":"2002","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2020.113135_bib46","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1177\/1947601912440575","article-title":"Quantitative methods for assessing drug synergism","volume":"2","author":"Tallarida","year":"2011","journal-title":"Genes Canc."},{"key":"10.1016\/j.ejmech.2020.113135_bib47","doi-asserted-by":"crossref","first-page":"5504","DOI":"10.1021\/jm0502788","article-title":"Design, synthesis, and antiviral activity of 2\u2019-deoxy-2\u2019-fluoro-2\u2019-C-methylcytidine, a potent inhibitor of hepatitis C virus replication","volume":"48","author":"Clark","year":"2005","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.113135_bib48","doi-asserted-by":"crossref","first-page":"5562","DOI":"10.2174\/0929867326666190816230650","article-title":"Small molecular gemcitabine prodrugs for cancer therapy","volume":"27","author":"Miao","year":"2020","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.113135_bib49","doi-asserted-by":"crossref","first-page":"261","DOI":"10.3390\/pharmaceutics5020261","article-title":"Preclinical absorption, distribution, metabolism, and excretion of an oral amide prodrug of gemcitabine designed to deliver prolonged systemic exposure","volume":"5","author":"Wickremsinhe","year":"2013","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejmech.2020.113135_bib50","first-page":"65","article-title":"Current prodrug strategies for improving oral absorption of nucleoside analogues","volume":"9","author":"Zhang","year":"2014","journal-title":"Asian J. Pharm. Sci."},{"key":"10.1016\/j.ejmech.2020.113135_bib51","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.ejpb.2013.12.009","article-title":"The development of orally administrable gemcitabine prodrugs with D-enantiomer amino acids: enhanced membrane permeability and enzymatic stability","volume":"86","author":"Tsume","year":"2014","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejmech.2020.113135_bib52","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1021\/mp049888e","article-title":"Amino acid ester prodrugs of the anticancer agent gemcitabine: synthesis, bioconversion, metabolic bioevasion, and hPEPT1-mediated transport","volume":"2","author":"Song","year":"2005","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejmech.2020.113135_bib53","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1021\/acs.jmedchem.7b00049","article-title":"Combination of l-carnitine with lipophilic linkage-donating gemcitabine derivatives as intestinal novel organic cation transporter 2-targeting oral prodrugs","volume":"60","author":"Wang","year":"2017","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.113135_bib54","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1158\/1078-0432.CCR-12-1184","article-title":"Human carboxylesterase-2 hydrolyzes the prodrug of gemcitabine (LY2334737) and confers prodrug sensitivity to cancer cells, Clinical cancer research","volume":"19","author":"Pratt","year":"2013","journal-title":"Off. J. Am. Assoc. Canc. Res."},{"key":"10.1016\/j.ejmech.2020.113135_bib55","doi-asserted-by":"crossref","first-page":"412","DOI":"10.3390\/molecules13020412","article-title":"Structure and catalytic properties of carboxylesterase isozymes involved in metabolic activation of prodrugs","volume":"13","author":"Hosokawa","year":"2008","journal-title":"Molecules"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523420311077?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523420311077?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:18:27Z","timestamp":1759328307000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523420311077"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":55,"alternative-id":["S0223523420311077"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2020.113135","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, synthesis, and evaluation of liver-specific gemcitabine prodrugs for potential treatment of hepatitis C virus infection and hepatocellular carcinoma","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2020.113135","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"113135"}}